School of Medicine
Showing 141-160 of 165 Results
-
Allyson Spence
Clinical Assistant Professor, Medicine - Oncology
BioAllyson Spence MD, PhD is a Clinical Assistant Professor of Medicine in the Stanford University School of Medicine. She received her MD, PhD in the MSTP program at Vanderbilt University School of Medicine, studying basic mechanisms of transcription using Saccharomyces cerevisiae as a model system in the laboratory of Dr. Tony Weil. She went on to an internship and residency at the University of Pennsylvania before returning to Stanford to complete her Oncology fellowship training. She did a postdoctoral fellowship at Stanford in the department of Molecular Biology under the auspices of Dr. Margaret Fuller, where she was the recipient of a career award.
She has transitioned from basic science research to clinical medicine where she sees patients diagnosed with breast cancer. Additionally, she has an appointment at the Palo Alto VA as a staff oncologist where she focuses on women's cancers and women at high risk of developing breast and gynecologic cancers. She is involved in several translational research projects at the VA, as well as being involved in clinical trials. -
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Frank E. Stockdale
Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsLaboratory and clinical research in breast cancer ; Normal and abornal differentiation and growth
-
Takeshi Sugio
Postdoctoral Scholar, Oncology
BioI am a physician-scientist and hematologist focused on clinical translation of T-cell biology. I received my MD from Kyushu University, and subsequently completed Residency Training at Toranomon Hospital, the largest transplant center in Japan. I continued my Hematology training at Kyushu University, where I qualified as a Board-certified specialist (2017) and supervisory hematologist (2021) by the Japanese Society of Hematology. For my PhD (2014-19), I studied expression profiles and histologic features of TCLs. I discovered distinct TCL clinical groups identified by infiltrating immune cell patterns in the microenvironment. Based on my dissertation work (Sugio, et al 2018 Blood Advances), I planned and conducted a Phase II trial of PD1 inhibition for relapsed/refractory TCL (UMIN000034499). I joined the Alizadeh lab at Stanford in 2021, where I am developing tools to analyze immune status using liquid biopsies.
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the development of Lexent Bio's liquid biopsy technology, first in response monitoring, overseeing scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director both in academia and private practice, he has firsthand understanding of unmet clinical needs of physicians and patients, and broad experience in clinical trial design and implementation.
He established the CA.RE.foundation, a cancer research foundation dedicated to enabling clinical trial execution across community oncology sites throughout the Northwest US. He’s independently built multiple software tools to help oncologists in the practical realities of their daily work.
Before Lexent Bio, he has served as Director of Translational Medicine at Genomic Health and as Vice President leading oncology development at Counsyl, integrating science with clinical product development. He is a steering committee member of the ASCO QOPI, a quality care initiative. -
Dr. Janaki Manoja Vinnakota
Affiliate, Medicine - Med/Oncology
Visiting Postdoctoral Scholar, Medicine - Med/OncologyBioJanaki Manoja Vinnakota PhD is a Junior Group Leader under Prof. Dr. Robert Zeiser in the Department of Hematology, Oncology, and Stem Cell Transplantation at the University Medical Center Freiburg, Germany. She is a visiting post-doctoral scholar under Prof. Dr. Dean Felsher, Division of Oncology, Stanford school of Medicine. Dr. Vinnakota’s research provided insights into understanding the pathomechanisms associated with central nervous system (CNS) related toxicities such as graft versus host diseases (CNS-GVHD), neurological immune related adverse events (nirAEs) and immune cell associated neurotoxicity syndrome (ICANS) and has most importantly unveiled therapeutic targets with high translational value. She identified the critical role of microglia/myeloid cells in mediating the neurotoxicity and cognitive impairment post diverse cancer immunotherapies. Her work on microglial Syk activation post immune checkpoint inhibition led to a translational application of the most promising and clinically available Syk inhibitor to target CNS irAEs. Dr. Vinnakota was awarded the highly competitive Hans A Krebs Medical Scientist grant, Germany to develop novel therapies that target CAR T cell associated toxicities.
Dr. Vinnakota holds a bachelor's and master's degree in engineering with a focus on biotechnology from IIT Madras, India. Her strong foundation in basic biology has enabled her to investigate projects with significant translational potential. For her Ph.D., Dr. Vinnakota studied the mechanisms of neurotoxicity following allogeneic stem cell transplantation and CAR T cell therapy. During her postdoctoral research, she expanded her expertise to explore neurotoxicity’s associated with immune checkpoint inhibition (anti-PD-1), the gut-microbiome axis in CNS-GVHD, and novel Kinase inhibition strategies to address GVHD.
Dr. Vinnakota was also honored with the prestigious Jan van Rood award from the EBMT society for her work on Targeting ICANS after CD19 CAR T cell therapy and she received the Prize for Innovative Research Approaches in Oncology by the Mertesmann Foundation, Germany for her work on the mechanisms of ICANS after CD19 CAR T cell therapy. Her contributions to immuno-oncology have been published in leading journals such as Nature Cancer, Science Translational Medicine, Journal of Clinical Investigation, and Nature Communications. -
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.
